How to buy Acasti Pharma stock - 05 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Acasti Pharma stock

Own Acasti Pharma stock in just a few minutes.


Fact checked

Acasti Pharma Inc is a biotechnology business based in the US. Acasti Pharma shares (ACST) are listed on the NASDAQ and all prices are listed in US Dollars. Acasti Pharma employs 32 staff and has a trailing 12-month revenue of around USD$81,000.

How to buy shares in Acasti Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Acasti Pharma. Find the stock by name or ticker symbol: ACST. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Acasti Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Acasti Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Acasti Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Acasti Pharma share price

Use our graph to track the performance of ACST stocks over time.

Acasti Pharma shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$0.18 - USD$1.22
50-day moving average USD$0.8027
200-day moving average USD$0.4224
Wall St. target priceUSD$2.52
PE ratio 25.9444
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.027

Buy Acasti Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Acasti Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Acasti Pharma under- or over-valued?

Valuing Acasti Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acasti Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Acasti Pharma's P/E ratio

Acasti Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Acasti Pharma shares trade at around 26x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).

Acasti Pharma financials

Revenue TTM USD$81,000
Gross profit TTM USD$0
Return on assets TTM -28.31%
Return on equity TTM 24.66%
Profit margin 3188.89%
Book value $0.165
Market capitalisation USD$125.4 million

TTM: trailing 12 months

Shorting Acasti Pharma shares

There are currently 1.8 million Acasti Pharma shares held short by investors – that's known as Acasti Pharma's "short interest". This figure is 20.5% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting Acasti Pharma shares can be evaluated.

Acasti Pharma's "short interest ratio" (SIR)

Acasti Pharma's "short interest ratio" (SIR) is the quantity of Acasti Pharma shares currently shorted divided by the average quantity of Acasti Pharma shares traded daily (recently around 59.3 million). Acasti Pharma's SIR currently stands at 0.03. In other words for every 100,000 Acasti Pharma shares traded daily on the market, roughly 30 shares are currently held short.

However Acasti Pharma's short interest can also be evaluated against the total number of Acasti Pharma shares, or, against the total number of tradable Acasti Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acasti Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Acasti Pharma shares in existence, roughly 10 shares are currently held short) or 0.0099% of the tradable shares (for every 100,000 tradable Acasti Pharma shares, roughly 10 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acasti Pharma.

Find out more about how you can short Acasti Pharma stock.

Acasti Pharma share dividends

We're not expecting Acasti Pharma to pay a dividend over the next 12 months.

Have Acasti Pharma's shares ever split?

Acasti Pharma's shares were split on a 1:10 basis on 15 October 2015. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acasti Pharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Acasti Pharma shares which in turn could have impacted Acasti Pharma's share price.

Acasti Pharma share price volatility

Over the last 12 months, Acasti Pharma's shares have ranged in value from as little as $0.18 up to $1.22. A popular way to gauge a stock's volatility is its "beta".

ACST.US volatility(beta: 1.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acasti Pharma's is 1.5195. This would suggest that Acasti Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Acasti Pharma overview

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site